AR119339A1 - DERIVADOS DE TIOFENO[3,2-b]PIRIDINA COMO INHIBIDORES DE eIF4E - Google Patents

DERIVADOS DE TIOFENO[3,2-b]PIRIDINA COMO INHIBIDORES DE eIF4E

Info

Publication number
AR119339A1
AR119339A1 ARP200101877A ARP200101877A AR119339A1 AR 119339 A1 AR119339 A1 AR 119339A1 AR P200101877 A ARP200101877 A AR P200101877A AR P200101877 A ARP200101877 A AR P200101877A AR 119339 A1 AR119339 A1 AR 119339A1
Authority
AR
Argentina
Prior art keywords
pyridine derivatives
thiophene
eif4e
inhibitors
alkyl
Prior art date
Application number
ARP200101877A
Other languages
English (en)
Inventor
Samuel Sperry
Alan X Xiang
Justin T Ernest
Siegfried H Reich
Paul A Sprengeler
Mike Shaghafi
Theo Michels
Christian Nilewski
Chinh Viet Tran
Garrick Kenneth PACKARD
Alan Grubbs
Kaveri Urkalan
Takasuke Mukaiyama
Original Assignee
Effector Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Effector Therapeutics Inc filed Critical Effector Therapeutics Inc
Publication of AR119339A1 publication Critical patent/AR119339A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Derivados de tieno[3,2-b]piridina como inhibidores del factor 4e de iniciación eucariótico (eIF4e); composición farmacéutica que los comprende y su utilización en el tratamiento de diversos tipos de cáncer incluyendo leucemia. Reivindicación 1: Un compuesto de la fórmula (1) o una sal farmacéuticamente aceptable del mismo, donde: L¹ es -(CH₂)-, -(CH₂)₂-, -(CH₂)₃-, -CH(alquilo C₁₋₈)(CH₂)-, -CH(alquilo C₁₋₈)(CH₂)₂-, -(CH₂)₂-O-, -CH₂CH=CH-, -CH₂C&
ARP200101877A 2019-07-02 2020-07-02 DERIVADOS DE TIOFENO[3,2-b]PIRIDINA COMO INHIBIDORES DE eIF4E AR119339A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962869662P 2019-07-02 2019-07-02

Publications (1)

Publication Number Publication Date
AR119339A1 true AR119339A1 (es) 2021-12-09

Family

ID=71614984

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101877A AR119339A1 (es) 2019-07-02 2020-07-02 DERIVADOS DE TIOFENO[3,2-b]PIRIDINA COMO INHIBIDORES DE eIF4E

Country Status (14)

Country Link
US (2) US11286268B1 (es)
EP (1) EP3994139A1 (es)
JP (1) JP2022539256A (es)
KR (1) KR20220061945A (es)
CN (1) CN114269756B (es)
AR (1) AR119339A1 (es)
AU (1) AU2020299362A1 (es)
BR (1) BR112021026682A2 (es)
CA (2) CA3085255A1 (es)
CL (1) CL2021003573A1 (es)
IL (1) IL289456A (es)
TW (1) TWI748541B (es)
UY (1) UY38773A (es)
WO (1) WO2021003157A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220378821A1 (en) * 2019-07-02 2022-12-01 Effector Therapeutics, Inc. Methods of treating braf-mutated cancer cells
WO2021240337A1 (en) * 2020-05-27 2021-12-02 Effector Therapeutics, Inc. Covalent modifiers of eif4e inhibiting compounds
US20240076301A1 (en) 2020-12-22 2024-03-07 Pfizer Inc. Solid Forms of an eIF4E Inhibitor
WO2024103069A1 (en) * 2022-11-10 2024-05-16 Ribometrix, Inc. COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
WO2014179237A1 (en) * 2013-04-29 2014-11-06 Vanderbilt University Substituted 3-benzylquinoxalin-4(3h)-one analogs as positive allosteric modulators of muscarinic acetycholine receptor m1
US9993494B2 (en) 2014-02-07 2018-06-12 Effector Therapeutics, Inc. Compositions and methods for treating fibrotic disease
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法

Also Published As

Publication number Publication date
TW202115058A (zh) 2021-04-16
EP3994139A1 (en) 2022-05-11
BR112021026682A2 (pt) 2022-03-15
US20230108594A1 (en) 2023-04-06
US11286268B1 (en) 2022-03-29
UY38773A (es) 2021-01-29
CA3085255A1 (en) 2021-01-02
CL2021003573A1 (es) 2022-08-12
KR20220061945A (ko) 2022-05-13
AU2020299362A1 (en) 2022-02-24
TWI748541B (zh) 2021-12-01
IL289456A (en) 2022-02-01
CN114269756A (zh) 2022-04-01
WO2021003157A1 (en) 2021-01-07
CA3188446A1 (en) 2021-01-07
JP2022539256A (ja) 2022-09-07
CN114269756B (zh) 2024-05-14

Similar Documents

Publication Publication Date Title
AR119339A1 (es) DERIVADOS DE TIOFENO[3,2-b]PIRIDINA COMO INHIBIDORES DE eIF4E
CL2022000271A1 (es) Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina.
NZ766835A (en) Pharmaceutical compounds
PH12020500485A1 (en) Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
CY1119771T1 (el) Ενωσεις αμινοπυριμιδινυλιου ως αναστολεις toy jak
EA038122B9 (ru) Ингибитор поверхностного антигена вируса гепатита b
EA201991693A1 (ru) Производное пиридина в качестве ингибитора ask1 и способ его получения и применения
PE20181093A1 (es) Compuestos heterociclicos y usos de los mismos
AR096758A1 (es) Inhibidores cristalinos de bromodominios
MX2019003143A (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
MX2017007748A (es) Compuestos de heteroarilo anulares fusionados y su uso como inhibidores del receptor de la tirocina cinasa (trk).
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
MX2017013797A (es) Inhibidor de janus quinasa.
MX2019010446A (es) Compuestos de anillos fusionados biciclicos derivados de piridilo como inhibidores de fgfr4.
TN2017000374A1 (en) TGF-β INHIBITORS
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
PH12020552017A1 (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
CO2021005532A2 (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
CL2022003045A1 (es) Quimioterápicos de éter macrocíclico heteroaromático solicitudes relacionadas
CL2019001694A1 (es) Compuestos de pirazolopirimidina y métodos de uso de los mismos.
AR094553A1 (es) Formas de oxadiazolpirazina
MX2018001992A (es) Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.
MX2017012295A (es) Derivados formilados n-heterociclicos como inhibidores de fgfr4.